Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival

By afschroeder • December 1, 2025

Crown J, Stroyakovskii D, Yardley DA, Huang CS, Fasching PA, Bardia A, Chia S, Im SA, Martin M, Xu B, Barrios CH, Untch M, Moroose R, Hurvitz SA, Hortobagyi GN, Slamon DJ, Visco F, Spera G, Zarate JP, Halligan D, Li Z, Loi S. Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival. ESMO Open. 2025 Nov;10(11):105858. doi: 10.1016/j.esmoop.2025.105858. Epub 2025 Oct 17. PMID: 41320342.

Tags: CDK4/6 inhibitor, early breast cancer, Hematology/Oncology, HR positive/HER2 negative, NATALEE, Publications, ribociclib

Susan Ettner, PhD and Dennis J. Slamon, MD, PhD Elected to the National Academy of Medicine

The UCLA Department of Medicine (DoM) is pleased to congratulate Susan Ettner, PhD and Dennis Slamon, MD, PhD, on their election to the National Academy[...]

B-Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20-Year-Old Woman

Cai J, Sin D, Varda M, Lewis L, Yeh J. B-Lymphoblastic Leukemia Presenting as Bilateral Ovarian Masses in a 20-Year-Old Woman. Clin Case Rep. 2026[...]

Putting the Patient at the Center of Patient-Centered Care

Rocque G, Nipp R, Sedrak MS. Putting the Patient at the Center of Patient-Centered Care. JCO Oncol Pract. 2026 Oct 16:OP2600798. doi: 10.1200/OP-26-00798. Epub ahead[...]